MCID: PTT003
MIFTS: 46

Pituitary-Dependent Cushing's Disease

Categories: Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

MalaCards integrated aliases for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease 11 14 16 71
Pituitary-Dependent Cushing Disease 11 31 33
Pituitary Acth Hypersecretion 43 33
Acth- [adrenocorticotropic Hormone] Secreting Pituitary Adenoma 33
Cushing Syndrome or Disease, Pituitary-Dependent 33
Pituitary-Dependent Hyperadrenocorticism 33
Pituitary-Dependent Cushings Disease 53
Pituitary-Dependent Hypercorticalism 33
Overproduction of Pituitary Acth 33
Corticotroph Pituitary Adenoma 33
Itsenko-Cushing Syndrome 33
Suprarenogenic Syndrome 33
Overproduction of Acth 11
Pituitary Basophilism 33
Cushings Basophilism 33
Cushing's Syndrome 3 33
Cushing's Disease 33
Cushing Disease 33
Itsenko Disease 33

Classifications:



External Ids:

Disease Ontology 11 DOID:3946
MeSH 43 D047748
NCIt 49 C113210
SNOMED-CT 68 190502001
ICD10 31 E24.0
ICD11 33 380861892
UMLS 71 C0221406

Summaries for Pituitary-Dependent Cushing's Disease

MalaCards based summary: Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to pituitary adenoma 1, multiple types and acth-independent macronodular adrenal hyperplasia. An important gene associated with Pituitary-Dependent Cushing's Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal cortex and adrenal gland, and related phenotypes are nervous system and homeostasis/metabolism

Related Diseases for Pituitary-Dependent Cushing's Disease

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 577)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 31.9 SST PRL GH1
2 acth-independent macronodular adrenal hyperplasia 31.3 POMC MC2R CRH
3 acth-secreting pituitary adenoma 30.9 USP8 USP48 SST PRL POMC NR3C1
4 abducens palsy 30.5 PRL POMC
5 diabetes insipidus 30.2 PRL POMC GH1 CRH
6 hypoadrenocorticism, familial 30.2 POMC MC2R CRH
7 graves disease 1 30.2 TRH POMC
8 withdrawal disorder 30.2 POMC CRH
9 multiple endocrine neoplasia 30.2 SST PRL POMC
10 premature ovarian failure 7 30.2 POMC GH1 CRH
11 pituitary tumors 30.1 SST PRL GH1
12 hypokalemia 30.1 POMC NR3C1 CRH
13 central diabetes insipidus 30.1 TRH PRL POMC GH1
14 carcinoid syndrome 30.1 SST GHRH
15 glucocorticoid deficiency 1 30.1 POMC MC2R
16 hypothyroidism, congenital, nongoitrous, 4 30.0 PRL POMC GH1
17 insulin-like growth factor i 30.0 SST PRL GHRH GH1
18 inappropriate adh syndrome 30.0 PRL POMC CRH
19 acne 30.0 PRL POMC CRH
20 somatoform disorder 30.0 POMC CRH
21 amenorrhea 29.9 TRH PRL POMC CRH
22 personality disorder 29.9 PRL NR3C1 CRH
23 acth deficiency, isolated 29.9 TRH PRL POMC CRH
24 hypogonadism 29.9 PRL POMC GH1
25 skin atrophy 29.9 POMC NR3C1
26 polycystic ovary syndrome 29.9 PRL POMC GH1
27 mood disorder 29.8 TRH POMC NR3C1 CRH
28 fibrous dysplasia 29.8 SST PRL GHRH GH1
29 craniopharyngioma 29.8 TRH PRL GH1
30 intracranial hypertension 29.8 PRL POMC
31 chiasmal syndrome 29.8 SST PRL POMC
32 adrenal adenoma 29.8 POMC MC2R CRH
33 adult syndrome 29.8 POMC NR3C1 CRH
34 post-traumatic stress disorder 29.8 POMC NR3C1 CRH
35 thyroid gland medullary carcinoma 29.8 SST POMC
36 pheochromocytoma 29.8 SST PRL POMC CRH
37 glucose intolerance 29.7 SST PRL POMC GH1
38 social phobia 29.7 PRL POMC CRH
39 acute stress disorder 29.7 POMC NR3C1 CRH
40 germinoma 29.7 PRL POMC
41 substance abuse 29.7 PRL POMC CRH
42 mental depression 29.7 POMC NR3C1 CRH
43 hyperandrogenism 29.7 PRL POMC NR3C1 GH1
44 goiter 29.7 TRH SST PRL
45 multiple endocrine neoplasia, type i 29.7 SST PRL POMC GHRH
46 chromophobe adenoma 29.6 TRH PRL POMC GH1
47 prolactinoma 29.6 TRH SST PRL POMC GH1
48 empty sella syndrome 29.6 TRH PRL POMC GH1
49 major depressive disorder 29.6 TRH SST PRL POMC NR3C1 CRH
50 adrenal cortical carcinoma 29.6 POMC MC2R CRH

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:



Diseases related to Pituitary-Dependent Cushing's Disease

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.09 CRH GH1 GHRH MC2R NR3C1 POMC
2 homeostasis/metabolism MP:0005376 10.02 CRH GH1 GHRH MC2R NR3C1 POMC
3 liver/biliary system MP:0005370 9.95 CRH GH1 GHRH NR3C1 POMC PRL
4 adipose tissue MP:0005375 9.91 CRH GH1 GHRH MC2R NR3C1 POMC
5 growth/size/body region MP:0005378 9.91 CRH GH1 GHRH MC2R NR3C1 POMC
6 no phenotypic analysis MP:0003012 9.85 CRH NR3C1 POMC SST TRH
7 endocrine/exocrine gland MP:0005379 9.76 CRH GH1 GHRH MC2R NR3C1 POMC
8 behavior/neurological MP:0005386 9.61 CRH GH1 GHRH MC2R NR3C1 POMC
9 immune system MP:0005387 9.23 CRH GH1 GHRH MC2R NR3C1 POMC

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
2
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
3
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
4
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
5
Cabergoline Approved Phase 4 81409-90-7 54746
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Lactitol Approved, Investigational Phase 4 585-86-4 157355
8 HIV Protease Inhibitors Phase 4
9
protease inhibitors Phase 4
10 Insulin, Globin Zinc Phase 4
11
Insulin Phase 4
12
Sitagliptin Phosphate Phase 4 654671-77-9
13 Dipeptidyl-Peptidase IV Inhibitors Phase 4
14 Incretins Phase 4
15 Hormone Antagonists Phase 4
16 Neurotransmitter Agents Phase 4
17 Dopamine agonists Phase 4
18 Dopamine Agents Phase 4
19 Antiparkinson Agents Phase 4
20
Ketoconazole Approved, Investigational Phase 3 65277-42-1, 142128-57-2 47576 3823 638701
21 Pharmaceutical Solutions Phase 3
22 Hypoglycemic Agents Phase 2, Phase 3
23 glucocorticoids Phase 2, Phase 3
24
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
25
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
26
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
27
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
28
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
29
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
30
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
31
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
32
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
33
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
34
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
35
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
36
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
37
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
38 Adrenocorticotropic Hormone Phase 2
39 Epinephryl borate Phase 2
40 Neuroprotective Agents Phase 2
41
Methylprednisolone Acetate Phase 2 584547
42 Protective Agents Phase 2
43 Histone Deacetylase Inhibitors Phase 2
44 Roscovitine Phase 2
45 Antiviral Agents Phase 2
46 Anti-Infective Agents Phase 2
47 Protein Kinase Inhibitors Phase 2
48
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 1 67-97-0, 1406-16-2 5280795 10883523
49 Vitamins Phase 1
50 Trace Elements Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
4 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
5 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
6 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
7 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
8 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
10 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
11 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
12 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
13 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
14 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
15 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
16 Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
17 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Completed NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
18 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
19 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
20 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
21 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
22 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease Recruiting NCT04339751 Phase 2 Vorinostat
23 SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome Recruiting NCT05307328 Phase 2 SPI-62;Placebo
24 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Active, not recruiting NCT03774446 Phase 2 Seliciclib
25 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
26 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
27 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
28 Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disorders (Acromegaly, Cushing's Disease, Primary Hyperparathyroidism, Diabetes Mellitus Type 1) Treated With Cholecalciferol Bolus Dose Completed NCT04844164 Phase 1 Cholecalciferol 15000 UNT/ML Oral Solution
29 Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI Unknown status NCT04121988
30 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892
31 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
32 Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease Completed NCT02568982
33 Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease Completed NCT03817840
34 Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease Completed NCT03346954
35 National Swedish Study in Cushing´s Disease Incidence and Outcomes Completed NCT02350153
36 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
37 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
38 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
39 Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease Completed NCT01459237 Early Phase 1 Acthrel
40 A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease Recruiting NCT04486859 LMWH/Rivaroxaban
41 Long-Term Follow-UP of Survivors of Pediatric Cushing Disease Recruiting NCT03831958
42 Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders Recruiting NCT04374721
43 Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease Recruiting NCT04201444
44 Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting NCT02310269 SOM230
45 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595
46 Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study Recruiting NCT03364803
47 Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study Recruiting NCT03974789
48 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
49 Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's Disease Not yet recruiting NCT04569591 Acthrel
50 A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7) Not yet recruiting NCT05633953 Osilodrostat

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Genetic Tests for Pituitary-Dependent Cushing's Disease

Anatomical Context for Pituitary-Dependent Cushing's Disease

Organs/tissues related to Pituitary-Dependent Cushing's Disease:

MalaCards : Pituitary, Adrenal Cortex, Adrenal Gland, Bone, Cortex, Thyroid, Brain

Publications for Pituitary-Dependent Cushing's Disease

Articles related to Pituitary-Dependent Cushing's Disease:

(show top 50) (show all 5540)
# Title Authors PMID Year
1
[Evaluation of the accuracy of inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome]. 53 62
17468067 2007
2
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. 53 62
15817922 2005
3
Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy. 53 62
11095430 2000
4
Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease. 53 62
10792343 2000
5
The modulation of glucocorticoid receptor content by 3-O-methyl-D-glucose transport in human mononuclear leukocyte in obesity. 53 62
9854680 1998
6
Differential diagnosis in cushing syndrome. Use of corticotropin-releasing hormone. 53 62
7891545 1995
7
A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. 53 62
7852498 1995
8
Differential release of proopiomelanocortin-derived peptides from the human pituitary: evidence from a panel of two-site immunoradiometric assays. 53 62
8157708 1994
9
Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. 53 62
8237244 1993
10
Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma. 53 62
1656408 1991
11
Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples. 62
36002784 2022
12
Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. 62
36251618 2022
13
Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France. 62
36470583 2022
14
Exoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a retrospective single-center study on 388 patients. 62
36136255 2022
15
Genetics of hyperaldosteronism and a wealth of new information on topics ranging from MEN1 to Cushing's disease and metabolic syndrome. 62
36380266 2022
16
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN. 62
36197784 2022
17
Pregnancy after pituitary surgery does not influence the recurrence of Cushing's disease. 62
35930216 2022
18
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). 62
36219274 2022
19
Dynamic testing for differential diagnosis of ACTH-dependent Cushing Syndrome: a systematic review and meta-analysis. 62
36453141 2022
20
Problem-solving therapy can reduce psychological distress in patients with Cushing's disease: a randomized controlled trial. 62
36050587 2022
21
Increased Risk of Ocular Hypertension in Patients With Cushing's Disease. 62
35980841 2022
22
Genetic drivers of Cushing's disease: Frequency and associated phenotypes. 62
36149413 2022
23
Corticotroph tumor progression speed after adrenalectomy. 62
36206174 2022
24
Management of Nelson's Syndrome. 62
36363537 2022
25
Correction of Hypercortisolemia with an Improved Cognitive Function and Muscle Mass after Transsphenoidal Surgery in an Older Patient with Cushing's Disease. 62
35491128 2022
26
New hope for a tumor-directed therapy fOR Cushing's disease. 62
36378569 2022
27
Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. 62
36470644 2022
28
Plurihormonal pituitary adenoma cosecreting ACTH and GH: a rare cause of Cushing's disease. 62
36410786 2022
29
Regression of venous thrombus after trans-sphenoidal hypophysectomy for pituitary-dependent hyperadrenocorticism in a dog. 62
36335913 2022
30
Reoperation for Recurrent and Persistent Cushing's Disease without Visible MRI Findings. 62
36431325 2022
31
Predictive Value of Early Postoperative Course of Serum Cortisol After Transsphenoidal Surgery for Cushing's Disease. 62
36084942 2022
32
How best to monitor the specific side effects of medical treatments of Cushing's disease. 62
36435719 2022
33
Multiple Deep Vein Thromboses After Curative Surgery for Cushing Disease: A Case Presentation and Review. 62
36447828 2022
34
11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing's disease. 62
36074938 2022
35
New mechanism of Cushing disease revealed. 62
36085417 2022
36
Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. 62
36327151 2022
37
Osilodrostat-induced adrenal insufficiency in a patient with Cushing's disease. 62
36415717 2022
38
Adrenal Cushing's Syndrome Treated With Preoperative Osilodrostat and Adrenalectomy. 62
36447826 2022
39
Is Desmopressin Useful in the Evaluation of Cushing Syndrome? 62
36103267 2022
40
Diagnostic accuracy of bilateral inferior petrosal sinus sampling using desmopressin or corticotropic- releasing hormone in ACTH-dependent Cushing's syndrome: A systematic review and meta-analysis. 62
35478451 2022
41
Cushing's disease in children: unique features and update on genetics. 62
35750967 2022
42
Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease. 62
35552989 2022
43
Genetics of Cushing's disease: from the lab to clinical practice. 62
35852754 2022
44
Role of Radiation in the treatment of Cushing Disease. 62
35687214 2022
45
Management of the incidental adrenal mass, continued surveillance versus surgical excision: analysis of US claims data on contemporary socio-demographic predictors and peri-operative outcomes. 62
36197701 2022
46
The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others? 62
36219200 2022
47
Treatment of Cushing's Disease with Pituitary-Targeting Seliciclib. 62
36214832 2022
48
Cushing's disease: adrenal steroidogenesis inhibitors. 62
36036308 2022
49
Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. 62
35980235 2022
50
Cushing's disease: role of preoperative and primary medical therapy. 62
35780261 2022

Variations for Pituitary-Dependent Cushing's Disease

Expression for Pituitary-Dependent Cushing's Disease

Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.

Pathways for Pituitary-Dependent Cushing's Disease

GO Terms for Pituitary-Dependent Cushing's Disease

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.92 PRL GH1

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.9 TRH PRL POMC NR3C1 MC2R GH1
2 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GHRH GH1
3 cell-cell signaling GO:0007267 9.23 TRH SST POMC GHRH

Molecular functions related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.4 TRH SST PRL POMC GHRH GH1
2 prolactin receptor binding GO:0005148 9.26 PRL GH1

Sources for Pituitary-Dependent Cushing's Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....